Recruitment of coregulator G9a by Runx2 for selective enhancement or suppression of transcription

Journal of Cellular Biochemistry

Volumn 113, Issue 7, 2012, Pages 2406-2414

  Purcell, Daniel J ^a,b   Khalid, Omar ^a   Ou, Chen Yin ^a,b   Little, Gillian H ^a   Frenkel, Baruch ^a   Baniwal, Sanjeev K ^a   Stallcup, Michael R ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

chromatin; Coregulator; G9a; Runx2; transcription

Indexed keywords

COLLAGENASE 3; COREPRESSOR PROTEIN; DOXYCYCLINE; G9A PROTEIN; GELATINASE B; HISTONE METHYLTRANSFERASE; LENTIVIRUS VECTOR; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER GROWTH; CHROMATIN IMMUNOPRECIPITATION; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; GENE EXPRESSION; GENE TARGETING; HISTONE METHYLATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION;

ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CHEMOKINE CXCL12; CORE BINDING FACTOR ALPHA 1 SUBUNIT; COS CELLS; CYSTATINS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HISTOCOMPATIBILITY ANTIGENS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MALE; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 9; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 84861084032     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24114     Document Type: Article

References (41)

1. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB,. 2010. Runx2 association with progression of prostate cancer in patients: Mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29: 811-821.
2. Baniwal SK, Khalid O, Sir D, Buchanan G, Coetzee GA, Frenkel B,. 2009. Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA. Mol Endocrinol 23: 1203-1214.
3. Baniwal SK, Khalid O, Gabet Y, Shah RR, Purcell DJ, Mav D, Kohn-Gabet AE, Shi Y, Coetzee GA, Frenkel B,. 2010. Runx2 transcriptome of prostate cancer cells: Insights into invasiveness and bone metastasis. Mol Cancer 9: 258.
4. Baniwal SK, Little GH, Chimge NO, Frenkel B,. 2012. Runx2 controls a feed-forward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferation. J Cell Physiol 227: 2276-2282.
5. Barnes GL, Hebert KE, Kamal M, Javed A, Einhorn TA, Lian JB, Stein GS, Gerstenfeld LC,. 2004. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res 64: 4506-4513.
6. Blyth K, Cameron ER, Neil JC,. 2005. The RUNX genes: Gain or loss of function in cancer. Nat Rev Cancer 5: 376-387.
7. Cameron ER, Neil JC,. 2004. The Runx genes: Lineage-specific oncogenes and tumor suppressors. Oncogene 23: 4308-4314.
8. Chimge NO, Baniwal SK, Little GH, Chen YB, Kahn M, Tripathy D, Borok Z, Frenkel B,. 2011. Regulation of breast cancer metastasis by Runx2 and estrogen signaling: Role of SNAI2. Breast Cancer Res 13: R127.
9. Chimge NO, Baniwal SK, Luo J, Coetzee S, Khalid O, Berman BP, Tripathy D, Ellis MJ, Frenkel B,. 2012. Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: In vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness. Clin Cancer Res 18: 901-911.
10. Dai J, Lu Y, Yu C, Keller JM, Mizokami A, Zhang J, Keller ET,. 2010. Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors. Cancer Res 70: 5014-5023.
11. Duan Z, Zarebski A, Montoya-Durango D, Grimes HL, Horwitz M,. 2005. Gfi1 coordinates epigenetic repression of p21Cip/WAF1 by recruitment of histone lysine methyltransferase G9a and histone deacetylase 1. Mol Cell Biol 25: 10338-10351.
12. Ducy P, Karsenty G,. 1995. Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol Cell Biol 15: 1858-1869.
13. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G,. 1997. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation. Cell 89: 747-754.
14. Epsztejn-Litman S, Feldman N, Abu-Remaileh M, Shufaro Y, Gerson A, Ueda J, Deplus R, Fuks F, Shinkai Y, Cedar H, Bergman Y,. 2008. De novo DNA methylation promoted by G9a prevents reprogramming of embryonically silenced genes. Nat Struct Mol Biol 15: 1176-1183.
15. Gyory I, Wu J, Fejer G, Seto E, Wright KL,. 2004. PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat Immunol 5: 299-308.
16. Ito Y,. 2004. Oncogenic potential of the RUNX gene family: 'Overview'. Oncogene 23: 4198-4208.
17. Kelly TK, De Carvalho DD, Jones PA,. 2010. Epigenetic modifications as therapeutic targets. Nat Biotechnol 28: 1069-1078.
18. Khalid O, Baniwal SK, Purcell DJ, Leclerc N, Gabet Y, Stallcup MR, Coetzee GA, Frenkel B,. 2008. Modulation of Runx2 activity by estrogen receptor-alpha: Implications for osteoporosis and breast cancer. Endocrinology 149: 5984-5995.
19. Koh SS, Chen D, Lee YH, Stallcup MR,. 2001. Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities. J Biol Chem 276: 1089-1098.
20. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T,. 1997. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89: 755-764.
21. Kos J, Lah TT,. 1998. Cysteine proteinases and their endogenous inhibitors: Target proteins for prognosis, diagnosis and therapy in cancer (review). Oncol Rep 5: 1349-1361.
22. Lee YM,. 2011. Control of RUNX3 by histone methyltransferases. J Cell Biochem 112: 394-400.
23. Lee DY, Northrop JP, Kuo MH, Stallcup MR,. 2006. Histone H3 lysine 9 methyltransferase G9a is a transcriptional coactivator for nuclear receptors. J Biol Chem 281: 8476-8485.
24. Lee SH, Kim J, Kim WH, Lee YM,. 2009. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells. Oncogene 28: 184-194.
25. Levanon D, Bettoun D, Harris-Cerruti C, Woolf E, Negreanu V, Eilam R, Bernstein Y, Goldenberg D, Xiao C, Fliegauf M, Kremer E, Otto F, Brenner O, Lev-Tov A, Groner Y,. 2002. The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons. EMBO J 21: 3454-3463.
26. Little GH, Noushmehr H, Baniwal SK, Berman BP, Coetzee GA, Frenkel B,. 2011. Genome-wide Runx2 occupancy in prostate cancer cells suggests a role in regulating secretion. Nucleic Acids Res. DOI: 10.1093/nar/gkr1219
27. Lo Coco F, Pisegna S, Diverio D,. 1997. The AML1 gene: A transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias. Haematologica 82: 364-370.
28. Lonard DM, O'Malley BW,. 2005. Expanding functional diversity of the coactivators. Trends Biochem Sci 30: 126-132.
29. Lonard DM, O'Malley BW,. 2007. Nuclear receptor coregulators: Judges, juries, and executioners of cellular regulation. Mol Cell 27: 691-700.
30. Nagano T, Mitchell JA, Sanz LA, Pauler FM, Ferguson-Smith AC, Feil R, Fraser P,. 2008. The Air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. Science 322: 1717-1720.
31. Nishio H, Walsh MJ,. 2004. CCAAT displacement protein/cut homolog recruits G9a histone lysine methyltransferase to repress transcription. Proc Natl Acad Sci USA 101: 11257-11262.
32. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen BR, Selby PB, Owen MJ,. 1997. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89: 765-771.
33. Ou CY, LaBonte MJ, Manegold PC, So AY, Ianculescu I, Gerke DS, Yamamoto KR, Ladner RD, Kahn M, Kim JH, Stallcup MR,. 2011. A coactivator role of CARM1 in the dysregulation of beta-catenin activity in colorectal cancer cell growth and gene expression. Mol Cancer Res 9: 660-670.
34. Purcell DJ, Jeong KW, Bittencourt D, Gerke DS, Stallcup MR,. 2011. A distinct mechanism for coactivator versus corepressor function by histone methyltransferase G9a in transcriptional regulation. J Biol Chem 286: 41963-41971.
35. Roopra A, Qazi R, Schoenike B, Daley TJ, Morrison JF,. 2004. Localized domains of G9a-mediated histone methylation are required for silencing of neuronal genes. Mol Cell 14: 727-738.
36. Schroeder TM, Jensen ED, Westendorf JJ,. 2005. Runx2: A master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res C Embryo Today 75: 213-225.
37. Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Ohki M, Fukuda M, Takeda N, Niida H, Kato H, Shinkai Y,. 2002. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev 16: 1779-1791.
38. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK,. 2002. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62: 1832-1837.
39. Westendorf JJ,. 2006. Transcriptional co-repressors of Runx2. J Cell Biochem 98: 54-64.
40. Woolf E, Xiao C, Fainaru O, Lotem J, Rosen D, Negreanu V, Bernstein Y, Goldenberg D, Brenner O, Berke G, Levanon D, Groner Y,. 2003. Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proc Natl Acad Sci USA 100: 7731-7736.
41. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW,. 1994. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells. Int J Cancer 57: 406-412.